IDSA Treatment Recommendations for Cryptococcal Meningoencephalitis in Human Immunodeficiency Virus Infected Individuals Induction therapy: • AmBd (0.7–1.0 mg/kg per day) plus flucytosine (100 mg/kg per day) - 2 weeks • Liposomal AmB (3–4 mg/kg per day) or ABLC (5 mg/kg per day, with renal function concerns) plus flucytosine (100 mg/kg per day) - 2 weeks • AmBd (0.7–1.0 mg/kg per day) or liposomal AmB (3–4 mg/kg per day) or ABLC (5 mg/kg per day, for flucytosine-intolerant patients) - 4–6 weeks Alternatives for induction therapy: • AmBd plus fluconazole • Fluconazole plus flucytosine • Fluconazole • Itraconazole Consolidation therapy: fluconazole (400 mg per day) 8 weeks Maintenance therapy: fluconazole (200 mg per day) > 1 year Alternatives for maintenance therapy: • Itraconazole (400 mg per day) >1 year • AmBd (1 mg/kg per week) >1 year #Cryptococcal #Meningoencephalitis #IDSA #Treatment #management #meningitis #cryptococcus #HIVAIDS
